Institute events
RSS feedEfgartigimod in Myasthenia gravis : the ADAPT phase III trial would have met its primary efficacy endpoint
An immunomodulatory biotherapy, efgartigimod is a fragment of antibodies directed against the neonatal Fc or FcRn receptors. These receptors prevent the breakdown of immunoglobulins G (IgG), which include the autoantibodies produced in myasthenia gravis. By binding to FcRn, efgartigimod (or ARGX-113) reduces the recycling of IgG and therefore their circulating rate. Administered as an infusion … [Read more]
COVID-19 and clinical trials in adults – 6 questions for Kubéraka Mariampillai
Interview with KubĂ©raka Mariampillai, Project Manager for the Adult Clinical Trials platform at the Institute of Myology, headed by Prof. Bertrand Fontaine and coordinated by Dr Giorgia Querin, and member of “Inflammatory Myopathies and Innovative Targeted Therapies” team 8 at the Research Centre, headed by Prof. Olivier Benveniste. If you could tell me who you … [Read more]
COVID-19 and psychological counselling : 5 questions for Prof. Marcela Gargiulo
Interview with Prof. Marcela Gargiulo, psychologist and leader of the team of psychologists at the Service of Neuro-Myology, headed by Prof. Bertrand Fontaine. If I could ask you who you are and what your mission is? I am a clinical psychologist and I have been working at the Institute of Myology since it was created … [Read more]
The Institute of Myology is recruiting a Helpdesk Assistant (M/F)
Located in Paris at the heart of the largest European hospital, PitiĂ©-SalpĂŞtrière, the Institute of Myology was created in 1996 by AFM-Telethon, a patient’s organization. The Institute of Myology coordinates, around the patient, medical care, basic research, applied research, clinical research and teaching. The main objective of the post is to promote and provide helpdesk … [Read more]
Study of grip strength in patients with DMD – Interview with J.-Y. Hogrel
The team at the Neuromuscular Physiology and Evaluation Laboratory of the Institute of Myology participated with, in particular, clinicians from I-Motion, in a study intended to assess grip strength in patients with Duchenne Muscular Dystrophy. The results were published in March 2020, in the Journal of Neurology*. Interview with Jean-Yves Hogrel, Head of the Laboratory. … [Read more]
COVID-19 and clinical research: 4 questions for Prof. Olivier Benveniste
Interview with Prof. Olivier Benveniste, Director of research Team 8, “Inflammatory myopathies and innovative targeted therapies“, at the Institute’s Centre for Myology Research, University Professor – Hospital Practitioner at the Department of Internal Medicine and Clinical Immunology (the DMIIC) at the PitiĂ©-SalpĂŞtrière Hospital, Coordinator for the French National Myositis Network. If you could provide some … [Read more]
COVID-19 and clinics: 4 questions for Dr Guillaume Bassez
Interview with Guillaume Bassez, research professor and neurologist at the Institute of Myology’s Service of Neuro-Myology. What measures have been put in place at the Service of Neuromyology to respond to the COVID-19 health crisis? Our service comprises 10 doctors: neurologists, rehabilitation doctors, psychologists and two interns. We usually handle 4200 consultations per year and … [Read more]
COVID-19 and clinical trials: 4 questions for Dr Giorgia Querin
Interview with Giorgia Querin, neurologist and Coordinating Doctor for the adult clinical trials platform at the Institute of Myology since January 2020. Â What measures have been put in place at the Service of Neuro-Myology and at the adult clinical trials platform in response to the COVID-19 health crisis? We have reviewed our organisation to … [Read more]
The Institute of Myology teams are mobilising to tackle COVID-19!
Our health professionals and researchers, who are on the frontline at the PitiĂ©-SalpĂŞtrière Hospital in Paris, are mobilising to help patients. All the health professionals and care practitioners in the Neuro-Myology Department have met to identify, as a priority, the most fragile neuromuscular patients in order to ensure their continued care and follow-up … [Read more]
Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study
Immunoglobulins are 2nd or 3rd-line treatments in dermatomyositis (DM) or polymyositis (PM) refractory to high-dose corticosteroids and immunosuppressants. Immunoglobulins (2 g/kg/mo) are usually administered intravenously (IVIg) once a month and the patients stay at hospital for a few days. Recently, subcutaneous injections (SCIg) were proposed 2 to 3 times per week, in some dysimmune diseases. SCIg … [Read more]